Peptide Initiative

Peptides · Peptide comparison

Leuprolide vs Triptorelin

A powerful GnRH agonist that helps manage hormone-sensitive conditions by controlling hormone production.

GnRH agonist that helps manage prostate cancer, endometriosis, and early puberty by controlling sex hormones

  • Hormone Support
  • Hormone Support

At a glance

Quick comparison

Dose rangeLeuprolide1–1 mgTriptorelin11.25–11.25 mg
FrequencyLeuprolideOnce dailyTriptorelinOnce daily
AdministrationLeuprolideSubcutaneous injection (daily)TriptorelinIntramuscular injection
Cycle lengthLeuprolideOngoing/indefiniteTriptorelinOngoing/indefinite
Onset speedLeuprolideModerate (1-2 weeks)TriptorelinModerate (1-2 weeks)
Evidence levelLeuprolideStrong human trials (Phase 3 or FDA approved)TriptorelinStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Cancer Management

Leuprolide94%
Triptorelin90%

Endometriosis & Fibroid Relief

Leuprolide90%
TriptorelinNo recorded rating

Hormone Control

Leuprolide87%
TriptorelinNo recorded rating

Hormone Regulation

LeuprolideNo recorded rating
Triptorelin94%

Endometriosis Relief

LeuprolideNo recorded rating
Triptorelin87%

Technical data

Compound specifications

Leuprolide

Molecular formula
C59H84N16O12
Molecular weight
1209.4 g/mol
Half-life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~95% (subcutaneous injection)
CAS number
74381-53-6

Triptorelin

Molecular formula
C64H82N18O13
Molecular weight
1311.4 g/mol
Half-life
2-3 hours (free peptide); 2-4 weeks (depot pamoate formulations)
Bioavailability
~100% (intramuscular/subcutaneous injection)
CAS number
57773-63-4

Protocols

Dosing compared

Leuprolide

Subcutaneous

  • 1 mgOnce daily · OngoingThe original daily form is a 1 mg shot under the skin each day for advanced prostate cancer. It works but needs a shot every day, so most people now use the longer-acting depot instead [4].

Intramuscular

  • 7.5 mgEvery month · OngoingThe 1-month depot is a single 7.5 mg shot into the muscle every 4 weeks. One injection replaces a month of daily shots [5].
  • 22.5 mgEvery 3 months · OngoingThe 3-month depot is a 22.5 mg muscle injection given once every 3 months, so fewer office visits [5].
  • 30-45 mgEvery 4-6 months · OngoingThe longest-acting depots: 30 mg every 4 months, or 45 mg every 6 months. These need only 2-3 injections per year [5].

Triptorelin

Intramuscular injection

  • 3.75 mgOnce every 4 weeks · Ongoing while indicatedFDA-labeled 1-month depot (Trelstar) for advanced prostate cancer; single IM injection into either buttock [5].
  • 11.25 mgOnce every 12 weeks · Ongoing while indicatedFDA-labeled 3-month depot (Trelstar). Strengths are not additive; chosen by desired interval [5].
  • 22.5 mgOnce every 24 weeks · Ongoing while indicatedFDA-labeled 6-month depot (Trelstar for prostate cancer; Triptodur 22.5 mg for central precocious puberty, ages 2+) [5][6].

Applications

Best suited for

Leuprolide

Managing advanced or metastatic prostate cancer
Leuprolide is particularly well-suited for individuals focused on managing advanced or metastatic prostate cancer. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][5].
Controlling severe endometriosis pain
Leuprolide is particularly well-suited for individuals focused on controlling severe endometriosis pain. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Treating symptomatic uterine fibroids
Leuprolide is particularly well-suited for individuals focused on treating symptomatic uterine fibroids. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].
Delaying early puberty in children
Leuprolide is particularly well-suited for individuals focused on delaying early puberty in children. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].

Triptorelin

Managing advanced prostate cancer when combined with other treatments
Triptorelin is particularly well-suited for individuals focused on managing advanced prostate cancer when combined with other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving severe endometriosis pain and symptoms
Triptorelin is particularly well-suited for individuals focused on relieving severe endometriosis pain and symptoms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Delaying puberty development in children with early sexual maturation
Triptorelin is particularly well-suited for individuals focused on delaying puberty development in children with early sexual maturation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Leuprolide

Common

  • Hot flashes (very common in men)
  • Decreased libido and erectile dysfunction
  • Injection site pain or swelling
  • Nausea
  • Fatigue
  • Mood changes or depression
  • Joint or muscle pain
  • Headaches
  • Dizziness
  • Thinning hair
  • Decreased bone density (osteoporosis with long-term use)
  • QT prolongation (rare but serious cardiac effect)
  • Tumor flare (temporary worsening of cancer symptoms in first weeks)
  • Severe allergic reactions
  • Spinal cord compression risk in men with metastatic disease

Serious

  • Severe allergic reaction

Triptorelin

No side effects recorded.

Research status

Safety & evidence

Leuprolide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Leuprolide (Lupron) is an FDA-approved GnRH agonist with 35+ years of clinical safety data involving millions of patients in oncology and endocrinology. [1] The critical safety issue is the initial 5-7 day flare effect—temporary surge in FSH/LH causing symptom worsening before hormone suppression begins—particularly dangerous for prostate cancer patients (flare can cause urinary obstruction or spinal cord compression). [5] Bone density loss is a dose-dependent long-term risk in both men and women requiring monitoring. [1][5] Injection site reactions, hot flushes, and initial hypogonadal symptoms are expected and typically transient. [5]

Contraindications

  • Pregnancy (may cause fetal harm) [6]
  • Undiagnosed vaginal bleeding [6]
  • Allergy to GnRH agonists or components [5][6]

Triptorelin

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Triptorelin (GnRH agonist) has extensive FDA-approved safety data spanning decades for prostate cancer, endometriosis, and precocious puberty indications. Initial testosterone surge upon initiation ("flare reaction") can worsen prostate cancer or spinal cord compression symptoms, requiring careful patient monitoring in first 1-2 weeks and use of androgen antagonists in high-risk patients. Hypogonadal effects including hot flashes, sexual dysfunction, and bone loss develop predictably with chronic GnRH suppression; bone density monitoring is recommended in patients on therapy >6 months.

Contraindications

  • Pregnancy (can affect fetal development)
  • Undiagnosed vaginal bleeding
  • Known hypersensitivity to GnRH agonists
  • Severe untreated depression
  • Active spinal cord compression in prostate cancer (requires urgent decompression)

Decision guide

Which is right for you?

Leuprolide

Choose Leuprolide if…

  • Managing advanced or metastatic prostate cancer
  • Controlling severe endometriosis pain
  • Treating symptomatic uterine fibroids
  • Delaying early puberty in children

Triptorelin

Choose Triptorelin if…

  • Managing advanced prostate cancer when combined with other treatments
  • Relieving severe endometriosis pain and symptoms
  • Delaying puberty development in children with early sexual maturation